XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 …
Over the last 12 months, insiders at XOMA Corporation have bought $0 and sold $0 worth of XOMA Corporation stock.
On average, over the past 5 years, insiders at XOMA Corporation have bought $8.82M and sold $1.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 250 shares for transaction amount of $3,473 was made by Sitko Bradley (Chief Investment Officer) on 2023‑10‑03.
2023-10-03 | Chief Investment Officer | 250 0.0022% | $13.89 | $3,473 | +74.42% | |||
2023-10-02 | Chief Investment Officer | 1,500 0.0133% | $14.25 | $21,375 | +71.54% | |||
2023-10-02 | Exec Chairman and Interim CEO | 1,000 0.0086% | $13.83 | $13,830 | +71.54% | |||
2023-09-26 | Exec Chairman and Interim CEO | 2,499 0.0221% | $14.43 | $36,061 | +67.84% | |||
2023-09-25 | Exec Chairman and Interim CEO | 1 <0.0001% | $14.65 | $15 | +62.26% | |||
2023-05-31 | Chief Investment Officer | 1,500 0.0132% | $17.13 | $25,700 | +6.76% | |||
2023-05-24 | Interim CEO | 1,032 0.012% | $23.79 | $24,551 | +0.22% | |||
2023-05-23 | Chief Investment Officer | 850 0.0076% | $19.00 | $16,150 | -4.09% | |||
2023-05-23 | Interim CEO | 968 0.0107% | $23.46 | $22,706 | -4.09% | |||
2023-05-19 | Chief Investment Officer | 1,000 0.0088% | $19.50 | $19,500 | -8.70% | |||
2023-05-16 | Chief Investment Officer | 500 0.0049% | $23.20 | $11,602 | -13.17% | |||
2023-05-15 | Chief Investment Officer | 1,500 0.0153% | $23.40 | $35,100 | -11.27% | |||
2023-05-12 | Chief Investment Officer | 2,000 0.0173% | $18.99 | $37,985 | -7.31% | |||
2023-01-06 | director | 3,249 0.0282% | $21.98 | $71,419 | -19.69% | |||
2023-01-06 | director | 1,573 0.0137% | $21.98 | $34,577 | -19.69% | |||
2023-01-05 | director | 19,000 0.1396% | $18.39 | $349,319 | -18.64% | |||
2023-01-05 | director | 15,670 0.1152% | $18.39 | $288,096 | -18.64% | |||
2022-07-15 | Sale | CEO | 20,883 0.1824% | $29.55 | $617,095 | -36.18% | ||
2022-07-15 | Sale | SVP, Finance & CFO | 2,000 0.0187% | $31.66 | $63,321 | -36.18% | ||
2022-03-21 | Sale | CEO | 2,339 0.021% | $30.02 | $70,209 | -33.94% |
BAKER JULIAN | director | 17888512 152.8345% | $32.50 | 1 | 0 | |
BVF PARTNERS L P/IL | director | 1618637 13.8292% | $32.50 | 48 | 0 | +31.12% |
PERRY MATTHEW D | See Explanation of Responses | 200000 1.7087% | $32.50 | 1 | 0 | <0.0001% |
DAVIS PETER B | VP, Finance & CFO | 94960 0.8113% | $32.50 | 1 | 0 | <0.0001% |
BAKER BROS. ADVISORS LP | other | 90538 0.7735% | $32.50 | 1 | 17 | +28.45% |
Bvf Inc Il | $87.39M | 31.22 | 3.63M | 0% | +$0 | 0.64 | |
Fidelity Investments | $27.91M | 9.97 | 1.16M | +0.48% | +$133,886.35 | <0.01 | |
BlackRock | $11.56M | 4.13 | 480,508 | -1.63% | -$191,846.86 | <0.0001 | |
The Vanguard Group | $9.75M | 3.48 | 405,533 | -3.78% | -$383,381.02 | <0.0001 | |
Stonepine Capital Management Llc | $6.1M | 2.18 | 253,770 | +1.51% | +$90,668.51 | 0.37 |